NASDAQ:GTHX - G1 Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $54.43
  • Forecasted Upside: 280.62 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$14.30
▲ +0.65 (4.76%)
1 month | 3 months | 12 months
Get New G1 Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GTHX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GTHX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$54.43
▲ +280.62% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for G1 Therapeutics in the last 3 months. The average price target is $54.43, with a high forecast of $82.00 and a low forecast of $21.00. The average price target represents a 280.62% upside from the last price of $14.30.
Buy
The current consensus among 8 investment analysts is to buy stock in G1 Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$66.00 ➝ $21.00Medium
i
10/5/2020HC WainwrightReiterated RatingBuy$82.00Medium
i
Rating by Edward White at HC Wainwright
8/20/2020WedbushReiterated RatingBuy$46.00Medium
i
8/18/2020HC WainwrightReiterated RatingBuy$82.00High
i
8/9/2020CowenReiterated RatingBuyHigh
i
8/6/2020WedbushLower Price TargetOutperform$50.00 ➝ $46.00High
i
8/3/2020Needham & Company LLCReiterated RatingBuy$74.00Medium
i
Rating by Chad Messer at Needham & Company LLC
8/3/2020HC WainwrightReiterated RatingBuyMedium
i
7/1/2020Needham & Company LLCReiterated RatingBuy$74.00Medium
i
Rating by Chad Messer at Needham & Company LLC
7/1/2020WedbushLower Price TargetOutperform$55.00 ➝ $50.00High
i
6/26/2020Roth CapitalInitiated CoverageBuy$55.00Medium
i
Rating by T. Butler at Roth Capital
6/22/2020Needham & Company LLCReiterated RatingBuy$74.00Low
i
5/12/2020JPMorgan Chase & Co.Lower Price TargetOverweight$33.00 ➝ $23.00High
i
2/27/2020WedbushLower Price TargetOutperform$67.00 ➝ $55.00High
i
1/21/2020HC WainwrightReiterated RatingBuy$72.00 ➝ $82.00High
i
Rating by Edward White at HC Wainwright
1/7/2020BTIG ResearchBoost Price TargetPositive ➝ Buy$51.00 ➝ $80.00Low
i
12/12/2019CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
12/12/2019Needham & Company LLCReiterated RatingBuy$74.00High
i
Rating by Chad Messer at Needham & Company LLC
12/12/2019HC WainwrightReiterated RatingBuy$72.00High
i
Rating by Edward White at HC Wainwright
11/6/2019CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
11/6/2019HC WainwrightReiterated RatingBuy$72.00High
i
Rating by Edward White at HC Wainwright
9/30/2019Needham & Company LLCSet Price TargetBuy$74.00Low
i
Rating by Chad Messer at Needham & Company LLC
9/30/2019CowenReiterated RatingBuyLow
i
Rating by Chris Shibutani at Cowen Inc
9/30/2019HC WainwrightSet Price TargetBuy$72.00Low
i
Rating by Edward White at HC Wainwright
9/27/2019B. RileySet Price TargetBuy$55.00Low
i
Rating by Harshita Polishetty at B. Riley
9/24/2019Needham & Company LLCSet Price TargetBuy$74.00Low
i
Rating by Chad Messer at Needham & Company LLC
9/13/2019CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
9/11/2019HC WainwrightReiterated RatingBuy$72.00High
i
8/8/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$38.00 ➝ $45.00High
i
6/18/2019CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
6/2/2019CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
5/10/2019CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
3/6/2019CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
3/1/2019WedbushReiterated RatingOutperform$67.00High
i
2/7/2019B. RileyInitiated CoverageBuy ➝ Buy$55.00 ➝ $55.00Medium
i
Rating by H. Polishetty at B. Riley
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$59.00 ➝ $41.00High
i
12/21/2018CowenReiterated RatingBuyMedium
i
12/20/2018WedbushReiterated RatingOutperform$67.00High
i
12/19/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-BuyHigh
i
11/11/2018CowenReiterated RatingBuyHigh
i
11/8/2018Needham & Company LLCLower Price TargetBuy$76.00 ➝ $74.00High
i
9/18/2018Needham & Company LLCBoost Price TargetBuy$76.00High
i
9/17/2018HC WainwrightReiterated RatingBuy$79.00Low
i
Rating by E. White at HC Wainwright
9/10/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$80.00High
i
8/10/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$58.00 ➝ $63.00Low
i
8/9/2018CowenReiterated RatingBuyHigh
i
5/29/2018HC WainwrightInitiated CoverageBuy$61.00Medium
i
Rating by E. White at HC Wainwright
5/18/2018Needham & Company LLCBoost Price TargetBuy$42.00 ➝ $60.00High
i
3/13/2018Needham & Company LLCBoost Price TargetBuy$42.00High
i
3/7/2018BTIG ResearchReiterated RatingBuy$48.00High
i
3/6/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$33.00 ➝ $39.00High
i
3/5/2018CowenReiterated RatingBuyLow
i
2/22/2018BTIG ResearchReiterated RatingBuy$38.00High
i
2/5/2018JPMorgan Chase & Co.Boost Price Target$30.00High
i
12/19/2017BTIG ResearchInitiated CoverageBuy$38.00Low
i
11/8/2017CowenReiterated RatingBuyN/A
i
8/9/2017CowenReiterated RatingBuyLow
i
6/12/2017WedbushInitiated CoverageOutperform$31.00High
i
Rating by D. Nierengarten at Wedbush
6/12/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$34.00High
i
6/12/2017CowenInitiated CoverageOutperform$31.00High
i
6/12/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$23.00High
i
(Data available from 11/29/2015 forward)
G1 Therapeutics logo
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Read More

Today's Range

Now: $14.30
$13.71
$14.50

50 Day Range

MA: $12.55
$10.99
$13.78

52 Week Range

Now: $14.30
$8.80
$31.38

Volume

750,535 shs

Average Volume

584,432 shs

Market Capitalization

$544.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.06